Van Cutsem E - Search Results

1

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.

Chung HC, Bang YJ, S Fuchs C, Qin SK, Satoh T, Shitara K, Tabernero J, Van Cutsem E, Alsina M, Cao ZA, Lu J, Bhagia P, Shih CS, Janjigian YY. Chung HC, et al. Among authors: van cutsem e. Future Oncol. 2021 Feb;17(5):491-501. doi: 10.2217/fon-2020-0737. Epub 2020 Nov 10. Future Oncol. 2021. PMID: 33167735 Free PMC article.

2

Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone.

van Cutsem E, Rutgeerts P, Vantrappen G. van Cutsem E, et al. Lancet. 1990 Apr 21;335(8695):953-5. doi: 10.1016/0140-6736(90)91010-8. Lancet. 1990. PMID: 1970032 Clinical Trial.

3

Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study.

Van Cutsem E, Filez L, Dewyspelaere J, Penninckx F, Janssens J. Van Cutsem E, et al. Anticancer Res. 1995 May-Jun;15(3):1079-80. Anticancer Res. 1995. PMID: 7645929 Clinical Trial.

4

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.

Van Cutsem E, Pozzo C, Starkhammar H, Dirix L, Terzoli E, Cognetti F, Humblet Y, Garufi C, Filez L, Gruia G, Cote C, Barone C. Van Cutsem E, et al. Ann Oncol. 1998 Nov;9(11):1199-204. doi: 10.1023/a:1008478405634. Ann Oncol. 1998. PMID: 9862050 Free article. Clinical Trial.

5

The treatment of advanced colorectal cancer: where are we now and where do we go?

Van Cutsem E, Verslype C, Demedts I. Van Cutsem E, et al. Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):319-30. doi: 10.1053/bega.2002.0288. Best Pract Res Clin Gastroenterol. 2002. PMID: 11969241 Review.

6

The role of chemotherapy in the current treatment of gastric cancer.

Van Cutsem E, Haller D, Ohtsu A. Van Cutsem E, et al. Gastric Cancer. 2002;5 Suppl 1:17-22. doi: 10.1007/s10120-002-0219-y. Gastric Cancer. 2002. PMID: 12772882 Review.

7

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Van Cutsem E, et al. Among authors: van de velde h. J Clin Oncol. 2004 Apr 15;22(8):1430-8. doi: 10.1200/JCO.2004.10.112. J Clin Oncol. 2004. PMID: 15084616 Clinical Trial.

8

The treatment of advanced gastric cancer: new findings on the activity of the taxanes.

Van Cutsem E. Van Cutsem E. Oncologist. 2004;9 Suppl 2:9-15. doi: 10.1634/theoncologist.9-suppl_2-9. Oncologist. 2004. PMID: 15161986 Free article. Review.

9

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E. Cassidy J, et al. Among authors: van cutsem e. J Clin Oncol. 2004 Jun 1;22(11):2084-91. doi: 10.1200/JCO.2004.11.069. J Clin Oncol. 2004. PMID: 15169795 Clinical Trial.

10

Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.

Van Laethem JL, Van Maele P, Verslype C, Polus M, Demols A, Houbiers G, Caenepeel P, Leleux A, Vermaut RR, Van Cutsem E, Peeters M. Van Laethem JL, et al. Among authors: van cutsem e, van maele p. Oncology. 2004;67(5-6):338-43. doi: 10.1159/000082916. Oncology. 2004. PMID: 15713988 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

719 results

Search Page